Hotgen Showcases Innovative Immunodiagnostic Solutions at ADLM 2026

At booth 4020, the company is presenting immunodiagnostic solutions designed to support accurate and efficient testing across clinical laboratories and other healthcare settings.

Hotgen’s portfolio is built around eight proprietary technology platforms and centers on chemiluminescence immunoassay systems, complemented by point-of-care and rapid testing products. The company is highlighting solutions intended to address different testing volumes and clinical applications, from centralized laboratories to emergency and primary care environments.

Among the featured products is the MQ60 Series Mono-test Chemiluminescence Immunoassay System. The platform supports a menu of more than 130 testing parameters and has accumulated over 18,000 installations worldwide. It is designed to provide accurate and efficient immunodiagnostic testing for laboratories of different sizes.

Hotgen is also showcasing its C800 and C2100 Series Chemiluminescence Immunoassay Systems. The automated platforms are designed to accommodate the testing requirements of healthcare institutions with different workload levels while providing flexible and reliable chemiluminescence immunoassay workflows.

For point-of-care applications, the company is presenting the UPT2800 testing system, which is powered by Hotgen’s proprietary Up-converting Phosphor Technology. The portable platform is designed to deliver rapid and accurate results for applications including primary healthcare, emergency diagnostics, and public health testing.

The company’s infectious disease portfolio at the event includes its TB-IGRA tuberculosis infection detection solution. Designed to support tuberculosis infection screening and clinical auxiliary diagnosis, the system provides testing capabilities for tuberculosis prevention and control programs. Hotgen is additionally exhibiting colloidal gold rapid tests and enzyme-linked immunosorbent assay products for a broader range of diagnostic applications.

Founded in 2005, Hotgen currently supplies products to more than 50 countries and regions. Its solutions have received international certifications, including European Union certification under the In Vitro Diagnostic Medical Devices Regulation, supporting their adoption across global immunodiagnostic markets.